Fig. 5

Secretome profile of HBPCs. A Timeline of CM collection. HBPCs were treated with LPS and/or PDGF-BB for 1 h, washed, cultured for 24 h, and CMs were collected. B Heat map of different protein levels in HBPC CM. The secreted levels of each factor are expressed as fold changes from the amount secreted in PBS CM. Colors from blue to red indicate a low to high protein level. C The top 12 proteins secreted in response to the stimulation are summarized in the graph. D Effects of inhibitors on the inflammatory priming of BMDMs by the pericyte secretome. BMDMs were pre-incubated with 1 μM SB225002 (CXCR1/2 inhibitor), 5 μM RS102895 (CCR2 inhibitor), or 100 nM C021 (CCR4 inhibitor) in serum-free RPMI 1640 media for 1 h, followed by a treatment with PBS CM or LPS + PDGF-BB CM for 12 h. Cells were then stimulated with 10 ng/mL LPS for 24 h, and Nos2 expression was measured as an index of inflammatory priming (n = 5). E mRNA level of CXCL5 in HBPCs treated with 100 ng/mL LPS and 100 ng/mL recombinant human PDGF-BB for 3 h (n = 6). F mRNA level of CXCL5 in HBPCs treated with 100 μM Palmitate (Pal) and 100 ng/mL recombinant human PDGF-BB for 6 h (n = 6). G Cxcl5 mRNA expression in the hypothalamus of FL and Pdgfrb^∆SYS-KO fed HFD for 4 weeks (n = 12–13). Data are presented as the mean ± SEM. *p < 0.05 and **p < 0.01, significantly different between each group